Innate Pharma S.A.
IPHA
$2.03
$0.021.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -78.75% | -80.47% | -74.11% | -73.59% | -76.80% |
| Total Other Revenue | -17.02% | -23.71% | -30.15% | -28.74% | -17.45% |
| Total Revenue | -58.49% | -61.84% | -64.09% | -63.37% | -69.63% |
| Cost of Revenue | -25.58% | -31.59% | -7.70% | -5.84% | -8.59% |
| Gross Profit | 1.31% | 9.27% | -379.17% | -388.81% | -289.19% |
| SG&A Expenses | 7.48% | -1.19% | 9.74% | 11.94% | 3.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.39% | -24.05% | -2.97% | -1.02% | -5.84% |
| Operating Income | -1.89% | 6.33% | -103.85% | -107.96% | -6,419.71% |
| Income Before Tax | 9.12% | 16.45% | -163.39% | -168.69% | -1,525.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.12% | 16.45% | -163.39% | -168.69% | -1,525.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.12% | 16.45% | -163.39% | -168.69% | -1,525.37% |
| EBIT | -1.89% | 6.33% | -103.85% | -107.96% | -6,419.71% |
| EBITDA | -3.37% | 4.97% | -115.63% | -119.97% | -997.03% |
| EPS Basic | 15.47% | 22.26% | -161.45% | -166.67% | -1,520.69% |
| Normalized Basic EPS | 15.44% | 22.33% | -161.08% | -166.58% | -1,510.96% |
| EPS Diluted | 14.93% | 21.87% | -161.45% | -166.67% | -1,673.58% |
| Normalized Diluted EPS | 15.44% | 22.33% | -161.08% | -166.58% | -1,614.71% |
| Average Basic Shares Outstanding | 7.50% | 7.50% | 0.80% | 0.80% | 0.69% |
| Average Diluted Shares Outstanding | 7.50% | 7.50% | 0.80% | 0.80% | -5.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |